Effect of prophylactic central compartment neck dissection on serum thyroglobulin and recommendations for adjuvant radioactive iodine in patients with differentiated thyroid cancer

Annals of Surgical Oncology

Volumn 19, Issue 13, 2012, Pages 4217-4222

  Wang, Tracy S ^a   Evans, Douglas B ^a   Fareau, Gilbert G ^a   Carroll, Ty ^a   Yen, Tina W ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; THYROGLOBULIN;

ADULT; AGED; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; NECK DISSECTION; REVIEW; THYROGLOBULIN BLOOD LEVEL; THYROIDECTOMY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NECK DISSECTION; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RADIOTHERAPY, ADJUVANT; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84876502486     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2594-x     Document Type: Review

References (22)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Pereira JA, Jimeno J, Miquel J, et al. Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. Surgery. 2005;138:1095-100.
3. Moo TA, Umunna B, Kato M, et al. Ipsilateral versus bilateral central neck lymph node dissection in papillary thyroid carcinoma. Ann Surg. 2009;250:403-8.
4. Popadich A, Levin O, Lee JC, et al. A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery. 2011;150:1048-57.
5. Teixeira G, Teixeira T, Gubert F, Chikota H, Tufano R. The incidence of central neck micrometastatic disease in patients with papillary thyroid cancer staged preoperatively and intraopera-tively as N0. Surgery. 2011;150:1161-7.
6. Laird AM, Gauger PG, Miller BS, Doherty GM. Evaluation of postoperative radioactive iodine scans in patients who underwent prophylactic central lymph node dissection. World J Surg. 2012; 36:1268-73.
7. Cisco RM, Shen WT, Gosnell JE. Extent of surgery for papillary thyroid cancer; preoperative imaging and role of prophylactic and therapeutic neck dissection. Curr Treat Options Oncol. 2012;13: 1-10.
8. Robbins KT, Shaha AR, Medina JE, et al. Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg. 2008;134:536-8. (Pubitemid 351724386)
9. Carty SE, Cooper DS, Doherty GM, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid. 2009;19:1153-8.
10. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19: 1167-214.
11. Sywak M, Cornford L, Roach P, Stalberg P, Sidhu S, Delbridge L. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery. 2006;140:1000-5.
12. Grubbs EG, Evans DB. Role of lymph node dissection in primary surgery for thyroid cancer. J Natl Compr Cancer Netw. 2007;5: 623-30. (Pubitemid 47057051)
13. Low TH, Delbridge L, Sidhu S, et al. Lymph node status influences follow-up thyroglobulin levels in papillary thyroid cancer. Ann Surg Oncol. 2008;15:2827-32.
14. Moo TA, McGill J, Allendorf J, Lee J, Fahey T 3rd, Zarnegar R. Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma. World J Surg. 2010; 34:1187-91.
15. Zetoune T, Keutgen X, Buitrago D, et al. Prophylactic central neck dissection and local recurrence in papillary thyroid cancer; a meta-analysis. Ann Surg Oncol. 2010;17:3287-93.
16. Shen WT, Ogawa L, Ruan D, et al. Central neck lymph node dissection for papillary thyroid cancer; comparison of complication and recurrence rates in 295 initial dissections and reoperations. Arch Surg. 2010;145:272-5.
17. Forest VI, Clark JR, Ebrahimi A, et al. Central compartment dissection in thyroid papillary carcinoma. Ann Surg. 2011;253: 123-30.
18. Carling T, Carty SE, Ciarleglio MM, et al. American thyroid association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. Thyroid. 2012;22:237-44.
19. SchroeDer PR, Haugen BR, Pacini F, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab. 2006;91:878-84. (Pubitemid 43357753)
20. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma; results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91:926-32. (Pubitemid 43357760)
21. Tuttle RM, Brokhin M, Omry G, et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med. 2008;49:764-70. (Pubitemid 351717542)
22. Evans DB. Papillary carcinoma of the thyroid; balancing principles of oncology with emerging technology. Surgery. 2011;150: 1015-22.